Results for &quot;&quot;Indinavir&quot;&quot;[mesh_terms]

Renal toxicity of protease inhibitors.

W M Bennett, A M deMattos, A J Olyaei

Current opinion in nephrology and hypertension 2001;9(5):473-6

Indinavir crystallization around the loop of Henle: experimental evidence.

J P Dieleman, S Salahuddin, Y S Hsu, D M Burger, I C Gyssens, M C Sturkenboom, B H Stricker, D J Kok

Journal of acquired immune deficiency syndromes (1999) 2003;28(1):9-13

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.

Wei Peng Yong, Jacqueline Ramirez, Federico Innocenti, Mark J Ratain

Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6699-704

Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.

Craig Hendrix, Charles W Flexner, Adriana S A Andrade, Teresa L Parsons, Chun-Su Yuan, Adrian S Dobs, Todd T Brown, Benjamin Caballero

BMC complementary and alternative medicine 2008;8():50

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

Diane Descamps, Véronique Joly, Philippe Flandre, Gilles Peytavin, Vincent Meiffrédy, Séverine Delarue, Stéphane Lastère, Jean-Pierre Aboulker, Patrick Yeni, Françoise Brun-Vézinet

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;33(2):99-103

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

F Chiodo, R Manfredi

The Journal of infection 2001;42(3):181-8

Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.

Tony Antoniou, Alice L Tseng, Rolf P G van Heeswijk, Scott E Walker, Pierre Giguere, Elizabeth J Phillips

Therapeutic drug monitoring 2006;27(6):779-81

Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

P O Markgren, M T Lindgren, K Gertow, R Karlsson, M Hämäläinen, U H Danielson

Analytical biochemistry 2001;291(2):207-18

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.

Marshall J Glesby, Judith A Aberg, Michelle A Kendall, Carl J Fichtenbaum, Richard Hafner, Stephen Hall, Nicole Grosskopf, Andrew R Zolopa, John G Gerber

Clinical pharmacology and therapeutics 2005;78(2):143-53

Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

Ulrik S Justesen, Zoe Fox, Court Pedersen, Pedro Cahn, Jan Gerstoft, Nathan Clumeck, Marcello Losso, Barry Peters, Niels Obel, Antonella Castagna, Ulrik B Dragsted, Jens D Lundgren

Basic & clinical pharmacology & toxicology 2007;101(5):339-44

Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.

Shyla Jagannatha, Raul Alfaro, Aaron H Burstein, Elizabeth Formentini, Stephen C Piscitelli, Judith Falloon

Pharmacotherapy 2002;22(5):551-6

HIV protease as a target for retrovirus vector-mediated gene therapy.

S Todd, C Anderson, D J Jolly, C S Craik

Biochimica et biophysica acta 2000;1477(1-2):168-88

Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.

D Konopnicki, S De Wit, B Poll, K Crommentuyn, A Huitema, N Clumeck

HIV medicine 2005;6(1):1-6

HIV therapy, metabolic syndrome, and cardiovascular risk.

Vivian Pao, Grace A Lee, Carl Grunfeld

Current atherosclerosis reports 2008;10(1):61-70